Travere Therapeutics (TVTX) Debt to Equity (2013 - 2025)

Travere Therapeutics has reported Debt to Equity for 13 years, with the latest figure at $2.1 in Q2 2025.

• For the quarter ending Q2 2025, Debt to Equity changed N/A year-over-year to $2.1; the trailing twelve-month figure through Jun 2025 stood at $2.1 (changed N/A YoY), and the FY2024 full-year result was $1.16, changed N/A from the prior year.
• Debt to Equity for Q2 2025 stood at $2.1, roughly flat from $2.09 in the prior quarter.
• The five-year high for Debt to Equity was $2.1 in Q2 2025, with the low at -$2.25 in Q3 2024.
• Historically, Debt to Equity has averaged $0.32 across 5 years, with a median of $0.06 in 2023.
• Annual changes were most pronounced in 2021 — Debt to Equity tumbled 70.27% — and 2022, when it soared 566.92%.
• Travere Therapeutics' Debt to Equity stood at $0.02 in 2021, then jumped by 566.92% to $0.16 in 2022, then sank by 63.74% to $0.06 in 2023, then jumped by 1862.55% to $1.16 in 2024, then surged by 80.82% to $2.1 in 2025.
• The last three Debt to Equity figures came in at $2.1 (Q2 2025), $2.09 (Q1 2025), and $1.16 (Q4 2024), per Business Quant data.